Altamira Therapeutics Ltd. (NASDAQ:CYTO – Get Free Report)’s stock price rose 1.8% on Tuesday . The stock traded as high as $0.93 and last traded at $0.92. 14,053 shares changed hands during trading, a decline of 98% from the average daily volume of 931,712 shares. The stock had previously closed at $0.91.
Altamira Therapeutics Trading Down 13.2 %
The business has a 50-day moving average price of $1.05 and a 200-day moving average price of $1.43.
About Altamira Therapeutics
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
See Also
- Five stocks we like better than Altamira Therapeutics
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Leveraged ETFs to Multiply Returns
- Insider Buying Explained: What Investors Need to Know
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
